$MSB

MESABI TRUST

Insider trades

No enriched coverage for $MSB in the last 7 days.

No SEC Form 4 filings for $MSB in the last 30 days.

See all $MSB insider activity →
Med

First Vietnamese bank surpasses $762mn in quarterly net interest income

Vietnam’s listed banks reported higher second-quarter 2026 net interest income versus the prior quarter, with only five banks declining. VietinBank led with a record VND20.7 trillion, first above VND20 trillion. BIDV, Vietcombank and VPBank also posted strong results. State Bank of Vietnam said system credit rose 8.38% to VND20.15 quadrillion by July 29.

MESABI TRUST (MSB): Results of Operations and Financial Condition

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. MESABI TRUST_July 30, 2026 0000065172 false 0000065172 2026-07-30 2026-07-30 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest e

Mesoblast Shares Break Resistance Following Latest Milestone

Mesoblast (ASX: MSB) shares rose after the company said its Phase 3 MSB-DR004 trial for rexlemestrocel-L in chronic lower back pain reached its target of at least 300 treated patients. The randomized, placebo-controlled study compares an intradiscal injection vs sham and follows patients for 12 months. The update removes an execution risk and supports a regulatory catalyst timeline.

MSB sentiment & insider activity

Recent MSB coverage spans earnings, technology and financial news.

What's driving MSB

  • Declining NII flags potential margin or balance-sheet headwinds and can weigh on near-term sentiment.

    news.tuoitre.vn · Aug 7, 2026

  • Royalty receipts and the $0 bonus royalty outcome are direct inputs to Mesabi Trust’s distributable cash, making the filing relevant for near-term income expectations.

    SEC EDGAR 8-K · Jul 31, 2026

  • The milestone is a near-term de-risking catalyst for rexlemestrocel-L, improving odds of progressing toward the next regulatory evidence step.

    thebull.com.au · Jul 15, 2026

  • The filing discloses a lower declared distribution, which can pressure income expectations and near-term valuation for MSB units.

    SEC EDGAR 8-K · Jul 14, 2026

  • The Metals Royalty Company (NASDAQ:TMCR) said its Mesabi Metallics royalty asset in Nashwauk, Minnesota completed its first production blast on July 10, 2026, fracturing about 211,000 tons of ore and opening the first pit ramp. TMCR expects ore to feed DR-grade pellets under a 1.0% index-priced gross overriding royalty with a revenue floor, targeting first pellet production in H2 2026 and potential annual royalty cash flow of about $11 million at 7.28 Mtpa.

    insidermonkey.com · Jul 13, 2026

alphai scores every news story that mentions MSB with an AI model for sentiment and relevance, and aggregates insider trades from MESABI TRUST's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MSB

Score

First Vietnamese bank surpasses $762mn in quarterly net interest income

Vietnam’s listed banks reported higher second-quarter 2026 net interest income versus the prior quarter, with only five banks declining. VietinBank led with a record VND20.7 trillion, first above VND20 trillion. BIDV, Vietcombank and VPBank also posted strong results. State Bank of Vietnam said system credit rose 8.38% to VND20.15 quadrillion by July 29.

$MSBLow

MESABI TRUST (MSB): Results of Operations and Financial Condition

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. MESABI TRUST_July 30, 2026 0000065172 false 0000065172 2026-07-30 2026-07-30 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest e

$MSBMed

Mesoblast Shares Break Resistance Following Latest Milestone

Mesoblast (ASX: MSB) shares rose after the company said its Phase 3 MSB-DR004 trial for rexlemestrocel-L in chronic lower back pain reached its target of at least 300 treated patients. The randomized, placebo-controlled study compares an intradiscal injection vs sham and follows patients for 12 months. The update removes an execution risk and supports a regulatory catalyst timeline.

$MSBMed

MESABI TRUST (MSB): Results of Operations and Financial Condition

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. MESABI TRUST_July 14, 2026 0000065172 false 0000065172 2026-07-14 2026-07-14 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest e

The Metals Royalty Company Announces Completion of First Production Blast at Mesabi Metallics

The Metals Royalty Company (NASDAQ:TMCR) said its Mesabi Metallics royalty asset in Nashwauk, Minnesota completed its first production blast on July 10, 2026, fracturing about 211,000 tons of ore and opening the first pit ramp. TMCR expects ore to feed DR-grade pellets under a 1.0% index-priced gross overriding royalty with a revenue floor, targeting first pellet production in H2 2026 and potential annual royalty cash flow of about $11 million at 7.28 Mtpa.

$MSBMed

Mesoblast Shares Lead ASX 200 Today: The Latest

Mesoblast (ASX: MSB) shares led ASX 200 gainers, up 4.91% to A$2.35, extending a two-week 24% rally. Bell Potter upgraded to Buy with a A$4.45 target. Mesoblast said it drew US$50m from a non-dilutive facility on June 25, and reported FDA BLA progress for Ryoncil (remestemcel-L) in late June and early July.

$MSBMedAI 8/10

Mesoblast Shares Lead The ASX 200 Into The Weekend

Mesoblast (ASX: MSB) shares rose 6.67% to A$2.24 after the company reported fourth-quarter net revenue of US$36 million for the three months ended 30 June 2026, above market expectations. Full-year revenue was US$115 million, driven by stronger US uptake of its Ryoncil therapy in paediatric transplant patients.

$MSBMed

Mesabi Trust Stock (ISIN: US5905971097) Holds Iron Ore Leverage as Commodity Rally Stalls

Mesabi Trust, an iron ore royalty trust, is trading below its net asset value as iron ore prices stabilize after recent volatility. The trust provides pure exposure to North American iron ore economics without operational risk, but its returns are directly tied to spot prices. European investors may find the current wider discount to NAV an attractive entry point, particularly with a long-term outlook on stable ore prices.

Related tickers